# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Shares of clinical stage biotech company Recursion Pharmaceuticals Inc (NASDAQ:RXRX) are trading higher Tuesday. The company...
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.
Recursion Pharmaceuticals shares traded higher Monday after the company provided updated guidance and partnership updates at it...
Access to Helix's large-scale clinico-genomic data to drive creation and training of AI modelsHelix, a leading population g...
Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to ad...